+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06762769

Evaluating Isatuximab, Iberdomide, and Dexamethasone Combination Therapy for Intermediate and High Risk Smouldering Myeloma

Led by University College, London · Updated on 2026-10-20

63

Participants Needed

14

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new combination of three drugsIsatuximab, Iberdomide, and Dexamethasonein adults with intermediate or high risk smouldering myeloma. This early form of myeloma can progress slowly to active multiple myeloma, and the study aims to see if this drug combination can prevent or delay disease progression while being tolerated and accepted by patients. Participants will receive treatment over two years, divided into 26 cycles of 28 days each, organized into three stages induction cycles 1-4, consolidation cycles 5-13, and maintenance cycles 14-26. Isatuximab is given subcutaneously via a medical device with varying frequency across stages, while Iberdomide and Dexamethasone are administered orally with specific dosing schedules throughout the treatment period. During the study, participants will be regularly monitored for treatment delivery and effectiveness, including response rates and safety. Researchers will assess progression-free survival, disease biomarkers, adverse events, and patient-reported outcomes through questionnaires and laboratory tests. Follow-up extends up to 5.5 years for long-term outcomes, with safety monitoring continuing for six months after treatment ends.

CONDITIONS

Brief Title

Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma

Research Team

M

MODIFY Trial Manager

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here